ࡗ ࡗ Purpose: To investigate the influence of diabetes mellitus on outcome after endovascular abdominal aortic aneurysm (AAA) repair. Methods: Of 6017 patients enrolled in the EUROSTAR registry after undergoing endovascular AAA repair between May 1994 and December 2003, 731 (12%) had diabetes mellitus (690 men; mean age 72 years, range 37-100). Patient demographics, risk factors, aneurysm morphology, operative and procedural details, complications, major events, and regular follow-up information were compared. The relationships of complications and events to diabetes mellitus, which were tested with multivariate logistic regression analysis and Cox proportional hazards modeling, are expressed as odds ratios (OR) and hazard rates (HR) with 95% confidence intervals (CI). Survival was compared with life-table analysis.
sessed as a comorbid factor that might impact the risk or outcome of EVAR. Diabetes is associated with accelerated rates of mortality, particularly from cardiovascular causes, and several chronic diseases, such as renal and peripheral occlusive diseases. 9 These comorbidities may increase the risk of open aneurysm repair, so it may be advantageous for diabetic patients with AAA to undergo EVAR. In this report, we investigate if patients with diabetes mellitus had different EVAR outcome than nondiabetics.
METHODS

Study Design
In July 1996, the EUROSTAR project was established with the objective of collecting and analyzing various aspects of endovascular AAA treatment. Data from patients operated before the start of the registry were retrieved retrospectively from hospital notes and patient records. Patient demographics, risk factors, aneurysm morphology, operative and procedural details, incidence of complications and major events (death, rupture, and conversion to open repair), and regular follow-up information were collected on standardized EUROSTAR Case Record Forms. The American Society of Anesthesiologists (ASA) risk classification and the Society for Vascular Surgery (SVS) risk score 10 were used to represent the patient risk profile. In the latter, risk scores of 1 and 2 indicated diet-controlled (oral hypoglycemic agent) or insulin-controlled type 2 diabetes, respectively; type 1 diabetes was indicated by a risk score of 3.
Intraoperative complications encompassed device-related sequelae, procedural failure, and arterial complications. Postoperative (inhospital) complications were grouped into systemic, procedure-and device-related, and access site/lower limb. Endoleaks discovered at the completion angiogram were also included in the 30-day complication assessment. Late complications included endoleaks, kinking, thrombosis, and migration occurring after 30 days. Follow-up examinations were performed at 1, 3, 6, 12, 18, and 24 months and yearly thereafter. 15 
Patient Population
Between May 1994 and December 2003, 6017 patients underwent endovascular AAA repair in 163 European centers (Appendix). Of these, 731 patients (690 men; mean age 72 years, range 37-100) had diabetes mellitus: 21 patients with type 1, 505 with diet-controlled type 2, and 205 with insulin-controlled type 2.
Data Analysis
Data were recorded on a computerized database. Odds ratios (OR) with 95% confidence intervals (CI) were calculated for time-independent variables with multivariate logistic regression analysis, while hazard rates (HR) were calculated using the Cox proportional hazards model for time-dependent characteristics. Both tests were used to test associations between complications and diabetes. The models were adjusted for patient age, sex, ASA classification, SVS risk factors, obesity, and unfitness for traditional open surgery or general anesthesia. In the Cox proportional hazard model for follow-up events, the immediate failures, patients lost to follow-up, and event-free observations were censored. Analyses were first performed for diabetic versus nondiabetic patients, and then the type 2 diabetic population was categorized as diet-controlled (oral hypoglycemic agent) versus insulin-controlled patients. Life-table analyses and Kaplan-Meier survival estimates were used to analyze survival. Statistical significance was set at pϽ0.05. Data analyses were performed with SAS statistical software (version 8.0; SAS Institutes, Cary, NC, USA).
RESULTS
The diabetic population had significantly higher proportions of several risk factors (Table 1), including hypertension (76% versus 61%), hyperlipemia (25% versus 15%), impaired cardiac function (41% versus 30%), carotid disease (11% versus 5%), renal disease (33% versus 17%), poor pulmonary status (25% versus 18%), and obesity (39% versus 24%). Owing to the greater preponderance of ASA class Ն3 risk (pϽ0.0001), diabetic patients were considered significantly more un- fit for open surgery and general anesthesia (pϽ0.0001). Device-related complications appeared significantly more often in diabetic patients (8% versus 6%, pϽ0.049) than in nondiabetics (OR 1.35, 95% CI 1.00 to 1.82) ( Table 2 ). Arterial complications, in particular, occlusion of the renal artery, occurred more frequently in patients with diabetes (1.1% versus 0.3%, pϽ0.010; OR 3.21, 95% CI 1.31 to 7.84). The 30-day mortality rate in the diabetic group (4%) was significantly higher than in the nondiabetic patients (2%, pϽ0.024; OR 1.67, 95% CI 1.07 to 2.61). There was no difference in early conversion or rupture rates. The higher mortality in the diabetic population was caused predominantly by cardiac complications (Table 3 ). Additional analyses of type 2 diabetics (Table 4 ) demonstrated a significantly lower proportion of early endoleaks in insulin-controlled (8%) compared to diet-controlled patients (17%, pϽ0.0023) and the nondiabetic (16%, pϽ0.0021) cohort.
Over a mean follow-up of 19.36Ϯ18.88 months (range 0-96), 59 patients were lost to follow-up (51 [1.0%] nondiabetics and 8 [1.1%] in the diabetic subgroup). Follow-up was complete in 70% of the population (Table  5 ). Different types of endoleaks occurred in similar proportions in diabetic and nondiabetic patients, as did kinking, stenosis, thrombosis, and migration. Late death occurred at comparable rates (both 9%). However, overall mortality was significantly higher in the diabetic population (13%) compared to the nondiabetic patients (10%, pϽ0.039; OR 1.27, 95% CI 1.01 to 1.59). No differences were found between the groups in late conversion or rupture rates. The cumulative survival rates after 48 months did not differ significantly: 74% in diabetics and 79% in the population without diabetes (Figure) .
Further analysis of type 2 diabetic patients ( mortality was noticed in the diabetic population. However, long-term cumulative survival was identical for diabetic versus nondiabetic patients, which we found when analyzing the correlation between diabetes and endovascular AAA repair. In our investigation of the relationship between diabetes and EVAR, patients with diabetes more often experienced device-related complications and arterial sequelae, such as occlusion of the renal artery. The most striking finding was the significantly higher 30-day mortality rate (4%) in the diabetic group, which was caused primarily by cardiac insufficiency. However, this higher early mortality rate was still in the 0% to 7% range reported by other recent studies analyzing EVAR. 1, 5, [12] [13] [14] de Virgilio et al. 15 compared cardiac morbidity and mortality between conventional and endovascular AAA repair, but in their study, diabetes was not a predictive criterion for an adverse cardiac event (pϭ0.07).
In type 2 diabetes, insulin treatment is used when diet, exercise, and oral agents are unable to establish adequate glycemic control. The United Kingdom Prospective Diabetes Study showed that improved glycemic condition in type 2 diabetes reduced vascular and all diabetes-related complications. 16, 17 Some authors have demonstrated a relationship between the duration of diabetes and the incidence of vascular complications, although the issue is disputed by several other investigators. [18] [19] [20] [21] [22] [23] [24] [25] Type 2 diabetes mellitus was frequently missed at diagnosis because hyperglycemia frequently was not severe enough to provoke characteristic symptoms of diabetes. Nevertheless, in this stage, patients are at increased risk of developing macrovascular and microvascular complications. 26, 27 The fact that elevated blood glucose levels may have been present for several months or even years before the diagnosis of type 2 diabetes is made complicates the analyses. Hence, the actual duration of type 2 diabetes cannot easily be estimated.
Compared to diet-controlled (oral hypoglycemic) or nondiabetic patients in our study, insulin-controlled type 2 diabetics had a significantly lower rate of endoleaks, which resulted in fewer secondary interventions. The lower incidence of endoleak in this patient group may be explained by the impact of diabetes on blood vessels. Diabetes affects the endothelial lining of arteries, causing them to become clogged with plaque, so the aortic Leurs et al.
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2005;12:288-296 side branches, including the lumbar, inferior mesenteric, internal iliac, and renal arteries, become less elastic and more occlusive. In addition, medication to help keep the blood glucose levels within a safe range or to control diabetes-related complications, such as high blood pressure or nephropathy (e.g., angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers), may influence the arterial condition and endoleak development. 9, 28 Riambeau et al. 29 analyzed the association between comorbidity and mortality after EVAR in patients considered unfit for open surgery. The survival curves in patients with poor medical condition were significantly worse than in those with a good medical status. However, the presence of co-existing diseases in patients unfit for open surgery did not affect the mortality rate. In our study population, the survival curves of diabetic and nondiabetic patients demonstrated similar cumulative survival after 4 years.
EUROSTAR, like any voluntary registry, has its advantages and disadvantages. The main advantages are the ability to gather a large amount of data on a diverse patient population in a relatively short period of time, address upcoming questions, evaluate longterm effectiveness, and include new devices or improvements. Disadvantages are a lack of randomization and double-blinding, a large interobserver variation, and less accurate and complete data. Nevertheless, a registry population normally is a good reflection of common day clinical practice.
Conclusions
Patients with diabetes had a significantly higher 30-day mortality rate then patients without diabetes. After a lower initial success rate, long-term survival was similar in both study groups. More assessment is needed to evaluate the effect of diabetes on EVAR outcome.
APPENDIX
EUROSTAR centers that contributed to this study:
